26 results
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
., 4 mg/kg on days ... CD4 count <200 cells ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
CD4 count <100 cells ... amphotericin B, 3 to 5 mg/kg ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
Acquired von Willebrand Syndrome - Diagnosis and Management
 • Autoantibodies to vWF: Lymphoproliferative disorders (e.g. lymphoma,
Diagnosis and Management ... Lymphoproliferative disorders (e.g ... adsorption onto cancer cells ... Syndrome #Diagnosis #Management ... treatment #hematology #differential
Bradycardia
1) First Steps: IV, O2, Monitors, ECG, Pads on patient, Crash Cart in room. Is patient
O2, Monitors, ECG ... Chest Pain • ECG ... Connect ECG Leads ... bradycardia #diagnosis #differential ... #management #cardiology
Approach to ECGs - Tachy/Bradyarrhythmias
Tachyarrhythmias - HR > 100
Wide
  (1) VT - DANGER
  (2)
block (lower AV cells ... bradyarrhythmia #ECG ... #EKG #diagnosis ... electrocardiogram #cardiology ... #differential
IDSA Recommendations for Treating Isospora belli Infection in HIV-AIDS
Treating Isospora belli Infection
General Management Considerations:
 • Fluid
Treating Isospora belli ... Infection General Management ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Benznidazole 5–8 mg/kg ... Nifurtimox 8–10 mg/kg ... Prevention #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
-6 activates T cells ... Tocilizumab 4-8mg/kg ... Siltuximab 11mg/kg ... Siltuximab #COVID19 #Pharmacology ... #Management #Medications
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
Differential Diagnosis ... Management during ... Management during ... Management during ... #cardiology #treatment
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Release from blast cells ... Prednisone 5mg/kg ... initiation • Differential ... APML #diagnosis #management